Elutia (ELUT) Competitors

Elutia (NASDAQ:ELUT) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.

Is ELUT or TERN more profitable?

Terns Pharmaceuticals has a net margin of 0.00% compared to Elutia's net margin of -218.72%. Elutia's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	-218.72%	N/A	-142.61%
Terns Pharmaceuticals	N/A	-32.76%	-31.33%

Does the media favor ELUT or TERN?

In the previous week, Elutia had 2 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 6 mentions for Elutia and 4 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.42 beat Elutia's score of 1.29 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Terns Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better earnings & valuation, ELUT or TERN?

Elutia has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$23.71M	3.09	-$37.66M	-$1.93	-0.92
Terns Pharmaceuticals	N/A	N/A	-$90.21M	-$1.09	-3.56

Do analysts rate ELUT or TERN?

Elutia currently has a consensus target price of $8.00, suggesting a potential upside of 349.44%. Terns Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 302.71%. Given Elutia's stronger consensus rating and higher possible upside, research analysts plainly believe Elutia is more favorable than Terns Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Terns Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Do insiders & institutionals believe in ELUT or TERN?

74.0% of Elutia shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 27.6% of Elutia shares are held by company insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in ELUT or TERN?

Terns Pharmaceuticals received 32 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 59.46% of users gave Terns Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Elutia	Outperform Votes 12 100.00%	Underperform Votes No Votes
Terns Pharmaceuticals	Outperform Votes 44 59.46%	Underperform Votes 30 40.54%

Which has more risk & volatility, ELUT or TERN?

Elutia has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.18, meaning that its share price is 118% less volatile than the S&P 500.

Summary

Elutia beats Terns Pharmaceuticals on 10 of the 17 factors compared between the two stocks.